Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;10(Suppl 3):S404-S411.
doi: 10.21037/jtd.2017.12.93.

Immunotherapy in surgically resectable non-small cell lung cancer

Dwight Owen  1 , Jamie E Chaft  2
Affiliations
Review

Immunotherapy in surgically resectable non-small cell lung cancer

Dwight Owen et al. J Thorac Dis. 2018 Feb.

Abstract

Surgical resection is the mainstay of therapy for patients with resectable and operable early stage non-small cell lung cancer (NSCLC). Surgery alone yields an unacceptably high rate of lung cancer recurrence. The addition of chemotherapy to surgery as adjuvant or neoadjuvant treatment can improve survival rates by roughly 5% at 5 years. Recently, major advances in cancer immunotherapy have led to better outcomes for many patients with lung cancer. Monoclonal antibodies to programmed death 1 and its ligand are now approved for both first and second line treatment patients with metastatic lung cancer. In this review, we will outline the rationale and current research strategies investigating the role of immunotherapy in resectable NSCLC.

Keywords: Immunotherapy; adjuvant; neoadjuvant; non-small cell lung cancer (NSCLC); surgery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Chaft serves as an advisor to Genentech, AstraZeneca, Bristol Meyers Squibb, and Merck. Dr. Owen has no conflicts of interest to declare.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30. 10.3322/caac.21387 - DOI - PubMed
    1. Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S-42S. - PubMed
    1. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27. 10.1016/S1470-2045(06)70804-X - DOI - PubMed
    1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. 10.1056/NEJMoa043623 - DOI - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed

LinkOut - more resources